At its meeting on 16 January 2023, the Transparency Council adopted Opinion No. 8/2023 on the evaluation of the medicine Ofev (nintedanib) under the drug programme “Treatment with nintedanib for interstitial lung disease of progressive phenotype with fibrosis (PF-ILD) (ICD-10 D86, J67.0-J67.9, J84.1, J84.8, J84.9, J99.0, J99.1)”,